A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell-Lung Cancer

被引：0
|
作者：
Harada, D. [1 ]
Kozuki, T. [1 ]
Nogami, N. [1 ]
Hotta, K. [2 ]
Aoe, K. [3 ]
Ohashi, K. [2 ]
Ninomiya, K. [2 ]
Hirata, T. [4 ]
Hinotsu, S. [5 ]
Toyooka, S. [6 ]
Kiura, K. [2 ]
机构：
[1] Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
[2] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[3] Yamaguchi Ube Med Ctr, Dept Med Oncol, Ube, Yamaguchi, Japan
[4] Kure Med Ctr, Dept Med Oncol, Kure, Japan
[5] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[6] Okayama Univ, Grad Sch Med, Gen Thorac Surg & Breast & Endocrinol Surg, Okayama, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
NSCLC; HER2; T-DM1;
D O I：
10.1016/j.jtho.2017.09.511
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 07.11
引用
收藏
页码：S1829 / S1829
页数：1
相关论文
共 50 条
  • [1] A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer
    Hotta, Katsuyuki
    Aoe, Keisuke
    Kozuki, Toshiyuki
    Ohashi, Kadoaki
    Ninomiya, Kiichiro
    Ichihara, Eiki
    Kubo, Toshio
    Ninomiya, Takashi
    Chikamori, Kenichi
    Harada, Daijiro
    Nogami, Naoyuki
    Hirata, Taizo
    Hinotsu, Shiro
    Toyooka, Shinichi
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (02) : 273 - 279
  • [2] Trastuzumab emtansine suppresses the growth of HER2-positive small-cell lung cancer in preclinical models
    Morimura, Osamu
    Minami, Toshiyuki
    Kijima, Takashi
    Koyama, Shohei
    Otsuka, Tomoyuki
    Kinehara, Yuhei
    Osa, Akio
    Higashiguchi, Masayoshi
    Miyake, Kotaro
    Nagatomo, Izumi
    Hirata, Haruhiko
    Iwahori, Kota
    Takimoto, Takayuki
    Takeda, Yoshito
    Kida, Hiroshi
    Kumanogoh, Atsushi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2017, 488 (04) : 596 - 602
  • [3] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [4] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [5] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [6] Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
    Waks, Adrienne G.
    Keenan, Tanya E.
    Li, Tianyu
    Tayob, Nabihah
    Wulf, Gerburg M.
    Richardson, Edward T.
    Attaya, Victoria
    Anderson, Leilani
    Mittendorf, Elizabeth A.
    Overmoyer, Beth
    Winer, Eric P.
    Krop, Ian E.
    Agudo, Judith
    Van Allen, Eliezer M.
    Tolaney, Sara M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (10)
  • [7] Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
    Gatzemeier, U
    Groth, G
    Butts, C
    Van Zandwijk, N
    Shepherd, F
    Ardizzoni, A
    Barton, C
    Ghahramani, P
    Hirsh, V
    ANNALS OF ONCOLOGY, 2004, 15 (01) : 19 - 27
  • [8] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [9] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [10] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
12345